Abstract
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
| Original language | English |
|---|---|
| Pages (from-to) | 927-35 |
| Number of pages | 9 |
| Journal | IDrugs: the Investigational Drugs Journal |
| Volume | 8 |
| Issue number | 11 |
| Publication status | Published - Nov 2005 |
